Not provided
Not provided
Not provided
Not provided
Business decision by the Sponsor
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A Randomized Clinical Trial of Ab Interno Canaloplasty and Trabeculotomy with the OMNI® Surgical System Compared to Standard Medical Treatment as a Standalone Procedure in Patients with Primary Open Angle Glaucoma (EVOLVE)
This prospective, multicenter, post-market clinical trial will evaluate the safety and effectiveness of canaloplasty and trabeculotomy using the OSS as a standalone procedure in patients with POAG.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Surgical (OMNI Surgical System (OSS)) | Active Comparator | Canaloplasty followed by Trabeculotomy using the OMNI Surgical System. |
|
| Standard Medical Care (SMC) | Active Comparator | Standard Medical Care with Latanoprost and one or two adjunctive glaucoma medications at the discretion of the Principal Investigator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| OMNI Surgical System | Device | The OMNI Surgical System is 510(k) cleared and indicated for canaloplasty (microcatheterization and transluminal viscodilation of Schlemm's canal) followed by trabeculotomy (cutting of trabecular meshwork) to reduce intraocular pressure in adult patients with primary open-angle glaucoma |
| Measure | Description | Time Frame |
|---|---|---|
| Subjects with a ≥ 20% reduction | Proportion of subjects with a ≥ 20% reduction from medicated baseline in mean diurnal IOP (DIOP) at 12 months post-operatively | 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Diurnal IOP (DIOP) between 6 and 18 mmHg (inclusive) | Proportion of eyes at 12 months post-randomization, with mean medicated diurnal IOP (DIOP) between 6 and 18 mmHg (inclusive). | 12 months |
| Number of Ocular Hypotensive Medications |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Any of the following prior ocular procedures:
Concurrent IOP-lowering procedure other than the study procedure (OSS) (e.g. ECP, CPC,etc.)
Forms of glaucoma other than POAG including but not limited to: Pigmentary, pseudoexfoliative, acute angle closure, normal tension, pre-perimetric, traumatic, congenital, malignant, uveitic, neovascular or severe glaucoma as documented in subject's medical record.
Women of childbearing potential if they are currently pregnant or intend to become pregnant during the study period; are breast-feeding; or are not in agreement to use adequate birth control methods to prevent pregnancy throughout the study
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| North Bay Eye Associates | Petaluma | California | 94954 | United States | ||
| University Eye Specialists |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Randomized controlled open label
Not provided
Not provided
Not provided
Not provided
|
|
| Latanoprost plus adjunctive glaucoma medication | Drug |
|
|
Mean number of ocular hypotensive medications used at 12 months
| 12 months |
| Tear break-up time (TBUT) | Proportion of eyes with a minimal clinically important difference (MCID) defined as a 1 category improvement, in tear beak-up time (TBUT) | 12 months |
| Corneal or conjunctival staining | Proportion of eyes with improvement in corneal staining or conjunctival staining by at least one category with no worsening in either at 12 months compared to baseline. | 12 months |
| OSDI score | Proportion of subjects with a MCID in ocular surface disease index (OSDI) score at 12 months compared to baseline | 12 months |
| Maryville |
| Tennessee |
| 37803 |
| United States |
| ID | Term |
|---|---|
| D005902 | Glaucoma, Open-Angle |
| ID | Term |
|---|---|
| D005901 | Glaucoma |
| D009798 | Ocular Hypertension |
| D005128 | Eye Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077338 | Latanoprost |
| ID | Term |
|---|---|
| D011461 | Prostaglandins F, Synthetic |
| D011465 | Prostaglandins, Synthetic |
| D011453 | Prostaglandins |
| D015777 | Eicosanoids |
| D005231 | Fatty Acids, Unsaturated |
| D005227 | Fatty Acids |
| D008055 | Lipids |
| D012898 | Autacoids |
| D018836 | Inflammation Mediators |
| D001685 | Biological Factors |
Not provided
Not provided